The estimated Net Worth of Randall J Steward is at least 7.29 百万$ dollars as of 3 August 2020. Mr. Steward owns over 21,166 units of QuidelOrtho stock worth over 1,077,028$ and over the last 13 years he sold QDEL stock worth over 4,629,650$. In addition, he makes 1,580,120$ as Chief Financial Officer at QuidelOrtho.
Sign up
Mr. Steward QDEL stock SEC Form 4 insiders trading
Randall has made over 8 trades of the QuidelOrtho stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 21,166 units of QDEL stock worth 390,724$ on 3 August 2020.
The largest trade he's ever made was exercising 94,215 units of QuidelOrtho stock on 28 July 2017 worth over 1,537,589$. On average, Randall trades about 6,242 units every 23 days since 2011. As of 3 August 2020 he still owns at least 24,014 units of QuidelOrtho stock.
You can see the complete history of Mr. Steward stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Randall Steward biography
Randall J. Steward serves as Chief Financial Officer of the Company. Prior to joining us, Mr. Steward served as the Chief Financial Officer for Navilyst Medical, Inc., a medical device company based in Massachusetts. From 2008 to January 2011, Mr. Steward served as Chief Operating Officer for SeQual Technologies, Inc., a San Diego-based medical device company, where he was responsible for all aspects of engineering, manufacturing, finance, and information systems. Prior to SeQual Technologies, Mr. Steward spent 11 years with Spectrum Brands as Executive Vice President and Chief Financial Officer. Mr. Steward holds a B.B.A. in Accounting from Southern Methodist University. He is also a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.
What is the salary of Randall Steward?
As the Chief Financial Officer of QuidelOrtho, the total compensation of Randall Steward at QuidelOrtho is 1,580,120$. There are 2 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of 4,168,770$.
How old is Randall Steward?
Randall Steward is 65, he's been the Chief Financial Officer of QuidelOrtho since 2014. There are 6 older and 22 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.
Insiders trading at QuidelOrtho
Over the last 21 years, insiders at QuidelOrtho have traded over 509,235,797$ worth of QuidelOrtho stock and bought 304,015 units worth 10,385,234$ . The most active insiders traders include Jack W Schuler、Matthew Strobeck、Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of 1,246,606$. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth 3,078,785$.
What does QuidelOrtho do?
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
What does QuidelOrtho's logo look like?
Complete history of Mr. Steward stock trades at QuidelOrtho
QuidelOrtho executives and stock owners
QuidelOrtho executives and other stock owners filed with the SEC include:
-
Douglas Bryant,
President, Chief Executive Officer, Director -
Douglas C. Bryant,
Pres, CEO & Director -
Randall Steward,
Chief Financial Officer -
Michael Abney,
Senior Vice President - Distribution -
Robert Bujarski,
Chief Operating Officer -
Ratan Borkar,
Senior Vice President - International Commercial Operations -
Werner Kroll,
Senior Vice President - R&D -
Edward Russell,
Senior Vice President - Business Development -
Robert J. Bujarski,
Chief Operating Officer -
Randall J. Steward,
Chief Financial Officer -
Dr. Werner Kroll,
Sr. VP of R&D -
Ratan S. Borkar,
Sr. VP of International Commercial Operations -
Robert J. Bujarski J.D.,
Pres & COO -
Kenneth Buechler,
Independent Chairman of the Board -
Edward Michael,
Independent Director -
Ken Widder,
Independent Director -
Charles Slacik,
Independent Director -
Matthew Strobeck,
Independent Director -
Mary Polan,
Independent Director -
Kathy Ordonez,
Independent Director -
Ruben Argueta,
Director - Investor Relations -
Ann Rhoads,
Director -
Karen Gibson,
Senior Vice President, Information Systems and Business Transformation -
Dr. Chockalingam Palaniappan Ph.D.,
Chief Innovation Officer -
Patrick E. Klein,
Chief Admin. Officer -
Louise Brandy,
Chief Information Officer -
Rhys de Callier,
VP of Strategy & Portfolio Management -
Dr. Johannes Kehle,
Pres of AnDiaTec Division -
Phillip S. Askim,
VP, Associate Gen. Counsel & Sec. -
Michael S. Iskra,
Chief Commercial Officer -
Joseph M. Busky CPA,
Chief Financial Officer -
Karen C. Gibson,
Sr. VP of Digital Health Bus. Unit -
Edward Keith Russell,
Sr. VP of Bus. Devel. -
Michael Donald Abney Jr.,
Sr. VP of North American Sales & Distribution -
Michelle A. Hodges,
Sr. VP & Gen. Counsel -
Group Inc.Carlyle Holdings ...,
-
Thomas D Brown,
Director -
Rodney F Dammeyer,
Director -
John Tamerius,
Sr. VP - Clinical/Reg Affairs -
Patrick Klein,
Chief Administrative Officer -
Louise Brandy,
SVP, Chief Information Officer -
Tamara A. Ranalli,
SVP, Molecular Bus. Unit -
Mark W Smits,
SVP-Commercial Operations -
Mark Pulido,
Director -
John Matthew Radak,
Chief Financial Officer -
Timothy Todd Stenzel,
Chief Science Officer -
Scot M Mc Leod,
Sr. VP - Operations -
Caren L Mason,
President and CEO -
Jack W Schuler,
Director -
Thomas James Foley,
Chief Technical Officer -
David R. Scholl,
Senior Vice President -
Richard C Iii Tarbox,
Sr. VP - Corporate Development -
Matthew T Heindel,
Sr. VP - Global Sales & Mrktg -
Douglas S Harrington,
Director -
Faye Wattleton,
Director -
Mark Paiz,
Senior Vice President -
Thomas A Glaze,
Director -
Paul E Landers,
Sr. V.P., CFO and Secretary -
S Wayne Kay,
President & CEO -
William J. Ferenczy,
SVP, Cardio/Metabolic Unit -
Michael S. Iskra,
EVP & CCO -
Christopher M Smith,
Director -
Joseph D Jr. Wilkins,
-
Evelyn S Dilsaver,
-
Joseph M Busky,
Chief Financial Officer -
James Prutow,
-
Michelle A. Hodges,
SVP, General Counsel